A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

NCT06039683 · clinicaltrials.gov ↗
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AstraZeneca